Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 9/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25947417 | 0.89 | MAPK14 (0.43) | MAPK14MAP4K1PSEN1PSEN2APH1B | |
| SCHEMBL21684882 | 0.87 | MAPK14 (0.47) | MAPK14MAP4K1 | |
| SCHEMBL21685680 | 0.83 | ALDH1A1 (0.50) | MAPK14MAP4K1 | |
| SCHEMBL25947747 | 0.83 | DHFR (0.43) | MAPK14MAP4K1PSEN1PSEN2APH1B | |
| SCHEMBL25947405 | 0.80 | MAP4K1 (0.50) | MAP4K1 | |
| SCHEMBL25947430 | 0.80 | MAP4K1 (0.58) | MAP4K1 | |
| SCHEMBL21685344 | 0.79 | MAPK14 (0.44) | MAPK14 | |
| SCHEMBL31304004 | 0.79 | MAPK14 (0.44) | MAPK14 | |
| SCHEMBL21685609 | 0.78 | MAP4K1 (0.64) | MAP4K1 | |
| SCHEMBL31304006 | 0.77 | DHFR (0.50) | MAPK14MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |